CN101945874A - 作为抗癌剂的3-取代的-4-氧代-3,4-二氢-咪唑并[5,1-d][1,2,3,5]-四嗪-8-甲酰胺类 - Google Patents

作为抗癌剂的3-取代的-4-氧代-3,4-二氢-咪唑并[5,1-d][1,2,3,5]-四嗪-8-甲酰胺类 Download PDF

Info

Publication number
CN101945874A
CN101945874A CN2008801269450A CN200880126945A CN101945874A CN 101945874 A CN101945874 A CN 101945874A CN 2008801269450 A CN2008801269450 A CN 2008801269450A CN 200880126945 A CN200880126945 A CN 200880126945A CN 101945874 A CN101945874 A CN 101945874A
Authority
CN
China
Prior art keywords
independently
compound according
saturated aliphatic
compound
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801269450A
Other languages
English (en)
Chinese (zh)
Inventor
M·F·G·史蒂文斯
D·卡森
S·詹宁斯
A·J·麦卡罗尔
J·G·威廉姆斯
M·G·休默索恩
J·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharminox Ltd
Original Assignee
Pharminox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharminox Ltd filed Critical Pharminox Ltd
Publication of CN101945874A publication Critical patent/CN101945874A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2008801269450A 2007-12-18 2008-12-16 作为抗癌剂的3-取代的-4-氧代-3,4-二氢-咪唑并[5,1-d][1,2,3,5]-四嗪-8-甲酰胺类 Pending CN101945874A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1452007P 2007-12-18 2007-12-18
US61/014,520 2007-12-18
PCT/GB2008/004140 WO2009077741A2 (en) 2007-12-18 2008-12-16 3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use

Publications (1)

Publication Number Publication Date
CN101945874A true CN101945874A (zh) 2011-01-12

Family

ID=40427129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801269450A Pending CN101945874A (zh) 2007-12-18 2008-12-16 作为抗癌剂的3-取代的-4-氧代-3,4-二氢-咪唑并[5,1-d][1,2,3,5]-四嗪-8-甲酰胺类

Country Status (12)

Country Link
US (2) US8450479B2 (https=)
EP (2) EP2698370A3 (https=)
JP (1) JP2011506588A (https=)
CN (1) CN101945874A (https=)
AR (1) AR071548A1 (https=)
AU (1) AU2008337261A1 (https=)
CA (1) CA2709749A1 (https=)
IL (1) IL206453A0 (https=)
PE (1) PE20091101A1 (https=)
TW (1) TW200934782A (https=)
WO (1) WO2009077741A2 (https=)
ZA (1) ZA201004554B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276415A (zh) * 2018-02-08 2018-07-13 台州职业技术学院 一种烷氧化三唑并四嗪类化合物及其制备方法和应用
CN113271939A (zh) * 2018-08-09 2021-08-17 伊利诺伊大学董事会 咪唑四嗪化合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091101A1 (es) 2007-12-18 2009-07-26 Pharminox Ltd AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO
CA2763766A1 (en) 2009-06-23 2010-12-29 Pharminox Limited 3-substituted-8-substituted-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use
US20130012706A1 (en) * 2010-03-01 2013-01-10 Pharminox Limited Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines
WO2012085501A1 (en) 2010-12-20 2012-06-28 Pharminox Limited 8 - sulfo - imidazotetrazin- 4 - one compounds and their use as anticancer drug
RU2545458C2 (ru) * 2013-08-01 2015-03-27 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" ПРОТИВОТУБЕРКУЛЕЗНОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО: КОМПОЗИЦИЯ ИМИДАЗО[1,2-b]ТЕТРАЗИНА С ПИРАЗИНАМИДОМ
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
KR20210093964A (ko) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
TW202039496A (zh) 2018-11-30 2020-11-01 美商默沙東藥廠 做為腺苷受體拮抗劑之9-經取代胺基三唑喹唑啉衍生物、醫藥組合物及其用途
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
GB201907813D0 (en) 2019-05-31 2019-07-17 Univ Nottingham Therapeutic compounds
KR102571751B1 (ko) 2020-03-24 2023-08-25 삼성에스디아이 주식회사 리튬 이차 전지의 전해질용 첨가제, 리튬 이차 전지용 전해질 및 이를 포함하는 리튬 이차 전지
US20240294478A1 (en) * 2021-06-18 2024-09-05 Yale University Anti-cancer compounds and methods of use
US20240400572A1 (en) * 2021-09-23 2024-12-05 Yale University Compounds and methods for treating cancers that are mgmt deficient regardless of mmr status
WO2023150569A1 (en) * 2022-02-01 2023-08-10 The Board Of Trustees Of The University Of Illinois Imidazotetrazine compounds and treatment of tmz-resistant cancers
KR20260047607A (ko) * 2023-08-04 2026-04-08 모디파이 바이오사이언시즈, 인크. 플루오로알콕시알킬렌-디히드로이미다조[5,1-d]테트라지논 화합물 및 관련 화합물 및 의학적 상태의 치료에서의 그의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) * 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
GB2125402B (en) 1982-08-17 1985-11-13 May & Baker Ltd New tetrazine derivatives
US4504475A (en) 1983-05-24 1985-03-12 Warner Lambert Company 3-(Haloethyl)-4-oxopyrazolo[5,1-D]-1,2,3,5-tetrazine-8-carboxamide compounds
GB9504361D0 (en) 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
CN101220033A (zh) 2001-01-18 2008-07-16 先灵公司 替莫唑胺和类似物的合成
PE20091101A1 (es) 2007-12-18 2009-07-26 Pharminox Ltd AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO
GB0807103D0 (en) 2008-04-18 2008-05-21 Univ Bradford The Compounds
CA2763766A1 (en) 2009-06-23 2010-12-29 Pharminox Limited 3-substituted-8-substituted-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276415A (zh) * 2018-02-08 2018-07-13 台州职业技术学院 一种烷氧化三唑并四嗪类化合物及其制备方法和应用
CN108276415B (zh) * 2018-02-08 2019-07-05 台州职业技术学院 一种烷氧化三唑并四嗪类化合物及其制备方法和应用
CN113271939A (zh) * 2018-08-09 2021-08-17 伊利诺伊大学董事会 咪唑四嗪化合物
US12234240B2 (en) 2018-08-09 2025-02-25 The Board Of Trustees Of The University Of Illinois Substituted imidazo[5,1-d][1,2,3,5]tetrazines for the treatment of cancer
CN113271939B (zh) * 2018-08-09 2025-03-07 伊利诺伊大学董事会 咪唑四嗪化合物

Also Published As

Publication number Publication date
CA2709749A1 (en) 2009-06-25
EP2698370A3 (en) 2014-07-16
IL206453A0 (en) 2010-12-30
WO2009077741A2 (en) 2009-06-25
AU2008337261A1 (en) 2009-06-25
ZA201004554B (en) 2011-09-28
EP2229393A2 (en) 2010-09-22
EP2698370A2 (en) 2014-02-19
JP2011506588A (ja) 2011-03-03
US8450479B2 (en) 2013-05-28
WO2009077741A3 (en) 2009-12-03
PE20091101A1 (es) 2009-07-26
AR071548A1 (es) 2010-06-30
TW200934782A (en) 2009-08-16
US20100286088A1 (en) 2010-11-11
US20130338104A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
CN101945874A (zh) 作为抗癌剂的3-取代的-4-氧代-3,4-二氢-咪唑并[5,1-d][1,2,3,5]-四嗪-8-甲酰胺类
TWI841759B (zh) 可用於治療流感病毒感染之化合物
EP3002285B1 (en) Tetrahydrocarboline derivative
EP2614061B1 (en) Quinoline and quinoxaline derivatives as kinase inhibitors
EP2585467B1 (en) Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents
EP2794611B1 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
CN102906090B (zh) 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
KR101561756B1 (ko) 이미다조 피라진
CN113214278A (zh) 新型Jak1选择性抑制剂及其用途
EP4137484A1 (en) Tricyclic compounds as egfr inhibitors
EP2445915B1 (en) 3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use
EP2740730B1 (en) Dibenzooxepin derivative
CN109311893B (zh) 含有取代环戊基的吡咯并嘧啶化合物
CN1269801A (zh) 作为抗病毒剂的嘌呤非环核苷
WO2019080724A1 (zh) 核苷磷酸类化合物及其制备方法和用途
HK1152526A (en) 3-substituted-4-0x0-3, 4-dihydro-imidazo- [5, 1-d] [1,2,3,5] -tetrazine-8-carboxylic acid amides as anticancer agents
US20210198282A1 (en) Salts of compounds and crystals thereof
WO2012085501A1 (en) 8 - sulfo - imidazotetrazin- 4 - one compounds and their use as anticancer drug
HK40035878A (en) Cyclic di-nucleotide compounds and methods of use
EP4212511A1 (en) Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof
AU740264C (en) Antiviral agents
HK1172321B (en) 3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use
HK1181754B (en) Quinoline and quinoxaline derivatives as kinase inhibitors
HK1184157B (en) Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1152526

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110112

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1152526

Country of ref document: HK